Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma

References

• Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52(12):1898–1907. doi:10.1038/s12276-020-00527-1
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Hao MZ, Lin HL, Chen QZ, et al. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma. J Dig Dis. 2017;18(1):31–39. doi:10.1111/1751-2980.12435
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Kan Z, Ivancev K, Lunderquist A. Peribiliary plexa--important pathways for shunting of iodized oil and silicon rubber solution from the hepatic artery to the portal vein. An experimental study in rats. Invest Radiol. 1994;29(7):671–676. doi:10.1097/00004424-199407000-00002
   PubMed Web of Science ®Google Scholar
• Terayama N, Matsui O, Gabata T, et al. Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization. Cardiovasc Intervent Radiol. 2001;24(6):383–387. doi:10.1007/s00270-001-0070-2
   PubMed Web of Science ®Google Scholar
• Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 2007;18(3):365–376. doi:10.1016/j.jvir.2006.12.004
   PubMed Web of Science ®Google Scholar
• Matsui O. Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. Clin Drug Investig. 2012;32(Suppl 2):3–13. doi:10.1007/BF03265492
   PubMedGoogle Scholar
• Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–116. doi:10.1002/hep.28453
   PubMed Web of Science ®Google Scholar
• Caine M, Chung T, Kilpatrick H, et al. Evaluation of novel formulations for transarterial chemoembolization: combining elements of lipiodol emulsions with drug-eluting beads. Theranostics. 2019;9(19):5626–5641. doi:10.7150/thno.34778
   PubMed Web of Science ®Google Scholar
• Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125–137. doi:10.1007/s12072-018-9919-1
   PubMed Web of Science ®Google Scholar
• Sidali S, Trepo E, Sutter O, et al. New concepts in the treatment of hepatocellular carcinoma. United European Gastroenterol J. 2022;10(7):765–774. doi:10.1002/ueg2.12286
   PubMed Web of Science ®Google Scholar
• National Cancer C, Liver Cancer Expert Committee Of National Cancer Quality Control C. 中国肝癌规范诊疗质量控制指标(2022版)[Quality control index for standardized diagnosis and treatment of primary liver cancer in China 2022]. Zhonghua Zhong Liu Za Zhi. 2022;44(7):600–608. Chinese. doi:10.3760/cma.j.cn112152-20220418-00265
   PubMedGoogle Scholar
• Kim DY, Toan BN, Tan CK, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin Mol Hepatol. 2023;29(2):277–292. doi:10.3350/cmh.2022.0212
   PubMed Web of Science ®Google Scholar
• Feng H, Li B, Li Z, et al. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1):401. doi:10.1186/s12885-021-08138-3
   PubMed Web of Science ®Google Scholar
• Soulen MC, Baere TD. Physics and physiology of transarterial chemoembolization and drug-eluting beads for liver tumors. Image-Guided Interventions in Oncology. 2020;3:29–42.
   Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Kudo M, Ikeda M, Ueshima K, et al. Response Evaluation Criteria in Cancer of the Liver version 5(RECICL 2019 revised version). Hepatol Res. 2019;49(9):981–989. doi:10.1111/hepr.13394
   PubMed Web of Science ®Google Scholar
• Hamashige S, Arquilla ER. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Principles and Practice of Clinical Trial Medicine. 2008;42:461–533.
   Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi:10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: asia-Pacific primary liver cancer expert consensus statements. Liver Cancer. 2020;9(3):245–260. doi:10.1159/000507370
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China From 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70(4):1119–1133. doi:10.1002/hep.30702
   PubMed Web of Science ®Google Scholar
• Cheng HY, Shou Y, Wang X, et al. Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT. World J Gastroenterol. 2004;10(18):2753–2755. doi:10.3748/wjg.v10.i18.2753
   PubMed Web of Science ®Google Scholar
• Chen MS, Li JQ, Zhang YQ, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol. 2002;8(1):74–78. doi:10.3748/wjg.v8.i1.74
   PubMed Web of Science ®Google Scholar
• Llovet JM, de Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313. doi:10.1038/s41575-020-00395-0
   PubMed Web of Science ®Google Scholar
• Kim CJ, Kim HJ, Park JH, et al. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int. 2014;34(2):305–312. doi:10.1111/liv.12270
   PubMed Web of Science ®Google Scholar
• Peng CW, Teng W, Lui KW, et al. Complete response at first transarterial chemoembolization predicts favorable outcome in hepatocellular carcinoma. Am J Cancer Res. 2021;11(10):4956–4965.
   PubMed Web of Science ®Google Scholar
• Cheng S, Chen M, Cai J, et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018). Liver Cancer. 2020;9(1):28–40. doi:10.1159/000503685
   PubMed Web of Science ®Google Scholar
• Kim GH, Kim JH, Shim JH, et al. Chemoembolization for single large hepatocellular carcinoma with preserved liver function: analysis of factors predicting clinical outcomes in a 302 patient cohort. Life. 2021;11(8):840. doi:10.3390/life11080840
   PubMedGoogle Scholar
• Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62(5):1187–1195. doi:10.1016/j.jhep.2015.02.010
   PubMed Web of Science ®Google Scholar
• Kakeda S, Korogi Y, Ohnari N, et al. Usefulness of cone-beam volume CT with flat panel detectors in conjunction with catheter angiography for transcatheter arterial embolization. J Vasc Interv Radiol. 2007;18(12):1508–1516. doi:10.1016/j.jvir.2007.08.003
   PubMed Web of Science ®Google Scholar
• Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, et al. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol. 2018;28(7):3032–3040. doi:10.1007/s00330-017-5198-9
   PubMed Web of Science ®Google Scholar
• de Baere T, Arai Y, Lencioni R, et al. Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol. 2016;39(3):334–343. doi:10.1007/s00270-015-1208-y
   PubMed Web of Science ®Google Scholar
• Laurent A, Wassef M, Saint Maurice JP, et al. Arterial distribution of calibrated tris-acryl gelatin and polyvinyl alcohol microspheres in a sheep kidney model. Invest Radiol. 2006;41(1):8–14. doi:10.1097/01.rli.0000188027.34400.f3
   PubMed Web of Science ®Google Scholar
• Stampfl S, Bellemann N, Stampfl U, et al. Arterial distribution characteristics of Embozene particles and comparison with other spherical embolic agents in the porcine acute embolization model. J Vasc Interv Radiol. 2009;20(12):1597–1607. doi:10.1016/j.jvir.2009.08.018
   PubMed Web of Science ®Google Scholar
• Dion JE, Rankin RN, Vinuela F, et al. Dextran microsphere embolization: experimental and clinical experience with radiologic-pathologic correlation. Work in progress. Radiology. 1986;160(3):717–721. doi:10.1148/radiology.160.3.2426727
   PubMed Web of Science ®Google Scholar